中
中文
繁体
English
About Us
About Us
Awards
Development Milestones
Our Culture
Social responsibility
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
Company News
Featured Report
With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030”
With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030”
Products
CNS Diseases
Oncology
Anti-infectives
Diabetes
Gastrointestinal
Cardiovascular
Hansoh is committed to innovation and research in the six therapeutic areas, including CNS, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Constantly
Hansoh is committed to innovation and research in the six therapeutic areas, including CNS, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Constantly
Hansoh is committed to innovation and research in the six therapeutic areas, including CNS, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Constantly
Hansoh is committed to innovation and research in the six therapeutic areas, including CNS, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Constantly
Hansoh is committed to innovation and research in the six therapeutic areas, including CNS, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Constantly
Hansoh is committed to innovation and research in the six therapeutic areas, including CNS, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. Constantly
Investor Relationships
Information Disclosure
Corporate Governance
Contact for Investors
Corporate Social Responsibility Report
As one of the few research-driven pharmaceutical companies ranking top in some treatment fields with the largest scale, the fastest growth and huge clinical demand...
As one of the few research-driven pharmaceutical companies ranking top in some treatment fields with the largest scale, the fastest growth and huge clinical demand...
As one of the few research-driven pharmaceutical companies ranking top in some treatment fields with the largest scale, the fastest growth and huge clinical demand...
As one of the few research-driven pharmaceutical companies ranking top in some treatment fields with the largest scale, the fastest growth and huge clinical demand...
R&D
R&D System
R&D Platform
R&D Achievements
National-level R&D Designations
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
Marketing Network
International Market
Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
搜索
Investor Relationships
Location:
Home
−
Investor Relationships
−
Information Disclosure
−
H Share
Information Disclosure
Corporate Governance
Contact for Investors
Corporate Social Responsibility Report
Search for
Select year
2019
Select month
search
Announcement and Circular
Performance Reports
Prospectus
2019
12-04
Announcement and Circular - [Monthly Return of Equity Issuer on Movements in Securities 20191130]
Online Browsing
2019
11-27
Announcement and Circular - [VOLUNTARY ANNOUNCEMNET-DRUG REGISTRATION APPROVAL OF FLUMATINIB MESYLATE]
Online Browsing
2019
11-04
Announcement and Circular - [Monthly Return of Equity Issuer on Movements in Securities 20191031]
Online Browsing
2019
10-17
Announcement and Circular - [VOLUNTARY ANNOUNCEMNET-DRUG REGISTRATION APPROVAL OF FOSAPREPITANT DIMEGLUMINE FOR INJECTION]
Online Browsing
2019
10-03
Announcement and Circular - [Monthly Return of Equity Issuer on Movements in Securities 20190930]
Online Browsing
2019
09-30
Announcement and Circular - [ANNOUNCEMENT ON DISTRIBUTION OF SPECIAL DIVIDEND]
Online Browsing
2019
09-26
Performance Reports - [2019 INTERIM REPORT]
Online Browsing
2019
09-03
Announcement and Circular - [Monthly Return of Equity Issuer on Movements in Securities 20190831]
Online Browsing
2019
08-30
Performance Reports - [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 ,2019]
Online Browsing
2019
08-20
Announcement and Circular - [DATE OF BOARD MEETING]
Online Browsing
2019
08-05
Announcement and Circular - [Monthly Return (July 2019) (EN)]
Online Browsing
2019
07-19
Announcement and Circular - [CHANGE OF ADDRESS OF HONG KONG SHARE]
Online Browsing
1
2
Next